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Background: Bisphosphonates (BP) are synthetic pyrophosphate-like substances with antiresorptive properties and 
specifically affect osteoclastic activity. In 2007, the American Association of Oral and Maxillofacial Surgeons 
(AAOMS) defined diagnostic criteria for Osteonecrosis of the Jaws Associated with Bisphosponates (BRONJ). 
BRONJ is mainly diagnosed by clinical features, but the detection of early bone changes by imaging may help 
prevent and better understand the disease. The objective of this study was to evaluate maxillary changes in CBCT 
in patients using BP. 
Material and Methods: All included patients were diagnosed with osteonecrosis and received bisphosphonate drugs 
in the last ten years. All imaging examinations were obtained by I-CAT and 3D Accuitomo. The multiplanar re-
constructions were analyzed by an examiner without knowledge of the clinical aspects and location of the lesions. 
Results: The study sample consisted of 21 patients, the majority of the sample represented patients with cancer 
(76.2%), the other patients had osteoporosis (23.8%). Only four patients (19.04%) received alendronate, while in-
travenous bisphosphonates, such as zoledronate and pamidronate, represented the treatment of most of our sample. 
Most of our patients presented stage 1 and 2 MRONJ (85.7%), whose lesions were mainly observed in the mandible 
(52.4%). Fifty-seven percent of the patients had at least one bone change. 
Conclusions: In BRONJ, bone changes vary between exposed and non-exposed areas and one aspect of the study 
was: persistent extraction cavities in the BRONJ lesion region and high frequency of periodontal ligament space 
widening in areas that are not involved in BRONJ lesions. This reflects the very important role of dental and pe-
riodontal diseases in the pathophysiology of BRONJ. Thus, preventive measures should be prioritized for patients 
exposed to anti-resorptive drugs.
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Introduction
Bisphosphonates (BP) are non-metabolic, synthetic, 
pyrophosphate-like substances with anti-resorptive pro-
perties. These drugs are indicated for several bone disea-
ses such as: osteoporosis, Paget’s disease, hypercalce-
mia of malignant tumors, bone metastases and multiple 
myeloma(1,2). BP specifically affect osteoclastic activi-
ty, decreasing the number of osteoclasts by apoptosis in-
duction. Consequently, the bone turnover is compromi-
sed. (3). In 2007, the American Association of Oral and 
Maxillofacial Surgeons (AAOMS) defined diagnostic 
criteria for BRONJ: current or previous BP treatment, 
exposed bone in the maxillofacial region that persisted 
for more than 8 weeks, and no history radiotherapy in 
the maxillary region (1). In 2014, AAOMS issued an up-
dated paper on this topic (4). The intake of nitrogen-con-
taining BP and the presence of local infection are known 
as the main risk factors for the disease. BRONJ is diag-
nosed primarily by clinical features, but radiological 
examinations are crucial to rule out hypotheses of other 
diseases as well as to evaluate the stage and extent of di-
sease (5). The detection of early bone changes by means 
of radiographic imaging could help preventing and be-
tter understanding the disease. Therefore, the objective 
of this study is to evaluate changes in CBCT jawbones 
under the influence of bisphosphonates.
Material and Methods
This study was approved by the Ethics Committee on 
Human Research of our institution (protocol number 
1.959.558). All patients included were diagnosed with 
BRONJ in accordance with the AAOMS diagnostic and 
staging criteria (6). Only patients who received bisphos-
phonate drugs in the past ten years were included in this 
research. Data regarding clinical aspects of BRONJ, sex, 
age and medical history were obtained from patients’ 
charts. The imaging exams were obtained with i-CAT 
(Xoran Technologies, Ann Arbor, Mich., And Imaging 
Sciences International, Hatfield, PA) and 3D Accuito-
mo XYZ Slice View Tomograph (J. Morita, Kyoto, Ja-
pan). CT scans with field of views including the entire 
maxilla, or mandible or both were included for analysis. 
Multiplanar reconstructions were analyzed by one exa-
miner unaware of the clinical aspects and location of the 
lesions. The presence of osteosclerosis, which is charac-
terized by hyperdense images on CBCTs, laminae dura 
thickening without endodontics association, maxillary 
sinus cortical thickening, maxillary sinus alteration, 
bone sequestrum, bone resorption in the jaws, persistent 
extraction socket, and discontinuation of the maxillary 
sinus floor, cortical mandibular and cortical mandibular 
canal were identified and quantified separately for each 
quadrant. Each tomographic finding was evaluated for its 
presence in relation to the clinical location of the lesion: 
if it was present in the region (quadrant) of the lesion, in 
another quadrant, or present in both. The frequency of 
bone changes in each quadrant was quantified.
Stastistical analysis were performed by IBM SPSS Sta-
tístics 17 software for Windows. Chi-squared test was 
applied to verify the association between the bone chan-
ges and MRONJ stage, and the significance level was 
set at 5%.
Results 
The study sample consisted of 21 patients (Table 1). Of 
those, 23.8% correspond to men and 76.2% to women. 
Considering the diagnosis, most of the sample repre-
sented cancer patients (76.2%). The remaining patients 
suffered from osteoporosis (23.8%). Diabetes was also 
a comorbidity seen in five patients. Concerning risk fac-
tors for BRONJ, the use of corticosteroids was obser-
ved in 28.6% of the patients and seven patients (33.3%) 
had previous history of a recent dental extraction. A 
long-term bisphosphonate therapy (more than 3 years) 
was found in 57.1% of the patients. Only four patients 
(19.04%) received alendronate, while intravenous bis-
phosphonate such as zoledronate and pamidronate 
represented the treatment of the majority of our sam-
ple. Most of our patients presented with stage 1 and 2 
BRONJ (85.7%), whose lesions were mainly seen in the 
mandible (52.4%). Dental implants as well as remaining 
tooth root were uncommonly seen in the area of BRONJ 
lesions (4.8%).
As bone changes, all of the following could be obser-
ved: widening of the periodontal ligament space wi-
thout endodontics association, thickened laminae dura, 
maxillary sinus cortical thickening, maxillary sinus al-
teration, thickening of the mandibular cortical, thicke-
ning of the mandibular canal cortical, osteosclerosis, 
bone sequestrum, bone resorption, persistent extraction 
socket, and discontinuation of the maxillary sinus floor 
(Table 2). In 57% of the patients one or more bone alte-
rations were present in the lesion region and in another 
region. Differences among the quadrant of BRONJ le-
sions and the others could be detected. In the region of 
BRONJ lesions, the most frequent bone changes were 
bone sequestrum (52.4%), persistent extraction socket 
(42.9%) and osteosclerosis (28.6%). On the other hand, 
changes such as widening of periodontal ligament space 
(33.3%) and maxillary sinus alteration (23.8%) followed 
by thickened mandibular canal cortical (19%) and bone 
resorption (19%) were the most recurrent in the other 
quadrants. Concerning the less common bone changes, a 
thickened lamina dura and maxillary sinus cortical were 
characteristics of quadrants with and without BRONJ 
lesion. While bone resorption could be barely seen near 
BRONJ lesions, bone sequestrum could be rarely noted 
in non-affected quadrants. 
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Age Sex Diagnosis Medication Months Usage MRONJ Site Recent 
extraction 
Stage
1 70 F Breast Cancer Zoledronate 12 Intravenous Left Palate No 2
2 74 F Breast Cancer Zoledronate 11 Intravenous Left Mandible No 0
3 47 F Breast Cancer Zoledronate 108 Intravenous Left Mandible No 1
4 60 F Breast Cancer Zoledronate 48 Intravenous Left and Right 
Maxilla
No 1
5 79 M Multiple mye-
loma
Zoledronate 36 Intravenous Left and Right 
Maxilla and Left 
Mandible
Yes 3
6 78 F Osteoporosis Alendronate 120 Oral Right Maxilla No 2
7 57 F Breast Cancer Pamidronate/ 
Zoledronate
24 Intravenous Left Mandible No 2
8 66 F Osteoporosis Alendronate 120 Oral Right Maxilla No 3
9 42 F Breast Cancer Pamidronate 168 Intravenous Right Mandible Yes 2
10 92 M Prostate Cancer Zoledronate 48 Intravenous Right Maxilla No 2
11 80 F Breast Cancer Zoledronate 84 Intravenous Right Maxilla No 1
12 72 F Kidney Cancer Zoledronate 12 Intravenous Left and Right 
Mandible
No 1
13 68 F Osteoporosis Alendronate 72 Oral Right Maxilla No 1
14 58 F Breast Cancer Zoledronate 60 Intravenous Left Mandible No 2
15 79 F Osteoporosis Alendronate 72 Oral Left and Right 
Mandible
No 1
16 84 F Osteoporosis Zoledronate/
Ibandronate
120 Intravenous / 
Oral
Left and Right 
Maxilla
No 1
17 62 M Prostate Cancer Zoledronate 14 Intravenous Left Mandible Yes 1
18 70 M Multiple mye-
loma
Zoledronate 18 Intravenous Right Mandible Yes 1
19 66 F Breast Cancer Pamidronate 60 Intravenous Left Maxilla Yes 1
20 68 F Breast Cancer Zoledronate 18 Intravenous Right Mandible Yes 1
21 63 M Colon Cancer Pamidronate 08 Intravenous Right Mandible Yes 1
Table 1: Clinical and prospective data from 21 patients.
Discussion
This work identified jaw bone changes among patients 
with BRONJ, describing tomographic findings in re-
gions with BRONJ lesions as well as in the non-affected 
ones. These areas without stablished BRONJ lesion mi-
ght reveal changes correspondent to effects of the antire-
sorptive drugs on bone. Comparing both regions, it was 
expected to find out alterations in bone that could point 
out early signs of BRONJ. In fact, this study showed 
tomographic signs near BRONJ lesions that were absent 
in non-affected sites and vice versa. Interestingly, Guo et 
al. could not detect any changes in the bony architecture 
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Widenig of the periodontal ligament space 19% 33,3% 19% 28,6% -
Laminae dura thickening 4,8% 4,8% - 90,5 -
Maxilar sinus cortical thickening 14,3% 4,8% - 61,9% 19%
Maxilar sinus alteration 23,8% 23,8% 14,3% 19% 19%
Thickening of the mandibular cortical 23,8% 9,5% 23,8% 33,3% 9,5%
Thickening of the mandibular canal cortical 23,8% 19% 4,8% 42,9% 9,5%
Osteosclerosis 28,6% 9,5% 33,3% 28,6% -
Presence of bone sequestrum 52,4% 4,8% - 42,9% -
Presence of Implants 4,8% 14,3% 4,8% 76,2% -
Presence of bone resorption 4,8% 19% 47,6% 28,6% -
Presence of persistent alveolus 42,9% 9,5% - 47,6% -
Presence of bone chages 33,3% - 57,1% 9,5% -
Discontinuation of the maxillary sinus floor 4,8% 9,5% - 85,7% -
Remaining tooth root 4,8% 4,8% - 90,5% -
Table 2: Prevalence of jaw changes on cone beam computed tomography.
on the non-osteonecrosis sites in the same patients with 
BRONJ by CBCT.
Even though studies on imaging of BRONJ have been 
conducted, none have contributed to determine early 
diagnosis of this condition (7). Their conclusions are 
even contradictory. Some researches postulated that the 
first evidence of BRONJ would be osteosclerosis and an 
active bone resorption would be present at advanced sta-
ges (8–12). Others claimed that the degree of sclerosis 
might increase as clinical severity of the condition pro-
gressed (13–16). In the present study, osteosclerosis was 
very frequent in BRONJ quadrants but not in non-com-
promised sites, so that it seemed to be related to advan-
ced BRONJ stages. Nonetheless, Wilde et al. presumed 
that this sign is generally insignificant in indicating the 
severity and extent of the BRONJ lesion, since it was 
irregularly distributed across all BRONJ stages in their 
study. Actually, the presence of osteosclerosis in clini-
cally symptomatic areas of the jaws has been described 
as a consistent tomographic finding, both in initial and 
advanced forms of osteonecrosis (14,17).
Besides sclerosis, osteolysis and sequestrum formation 
were frequent findings in stage 1 and 2 BRONJ, and uni-
versal in Stage 3 BRONJ (11,17). Corroborating these 
outcomes, our work showed that bone sequestrum was 
markedly a common finding near BRONJ lesions and 
the less recurrent one in other regions, but bone resorp-
tion could be frequently noted in all areas. However, the-
se well-recognized tomographic features have not been 
found consistently and have been mainly associated 
with advanced stages of this disease (12,14). 
Also, thickening of the lamina dura and alveolar crest 
have been considered as the most common radiographic 
features in patients taking bisphosphonate (12,18). They 
might indicate a higher risk for BRONJ and have been 
related to its early stages (9,10,12,19).  Differently, a 
thickened lamina dura was hardly found near MRONJ 
lesions and in non-affected sites in our study. However, 
we could often see a widening of periodontal ligament 
space in areas other than involved in BRONJ lesions. 
Associated with the high frequency of persistent extrac-
tion sockets (42.9%) in the region of BRONJ lesions 
also observed in our study, a main role of dental and pe-
riodontal diseases in the development of BRONJ could 
be unveiled for our sample. This is in line with recent 
outcomes evidenced by a systematic review (7). 
A significant increase in mandibular cortical thickness 
was verified by CBCT in case-control studies (16,20,21). 
Confirming these data, two retrospective studies asses-
sed the mandibular cortical width by comparing CBCTs 
obtained from patients with BRONJ, patients under an-
tiresorptive therapy without symptoms of BRONJ and 
patients without history of antiresorptive medication use 
and symptoms of BRONJ (22,23). Their results pointed 
out a significant difference in cortical bone width be-
tween BRONJ and control groups, but no correlation 
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could be found between non-BRONJ and control ca-
tegories. Additionally, the low interobserver reliability 
between the two observers is a major bias in one of these 
studies. Another case-control study (24) evaluating the 
mandibular cortical width and the height from the in-
ferior mandibular border to the mental foramen in 46 
Caucasian women receiving oral bisphosphonates wi-
thout BRONJ demonstrated that both measurements 
should not be used to predict the risk of this condition. 
Our study revealed a thickened mandibular cortical bone 
near BRONJ lesions and even in other areas. In other 
words, mandibular cortical thickness is a measurement 
that hardly differentiate patients taking antiresorptive 
agents without BRONJ from other groups. Consequent-
ly, it is challenging to predict the incidence of BRONJ 
using only this parameter.
A thickened mandibular canal cortical has been advo-
cated as an early sign of BRONJ (7,12). Nonetheless, 
it was a recurrent sign in areas with and without osteo-
necrosis in the present study. A case-control study mea-
sured the diameter and width of mental foramen as well 
as the diameter of incisive canal, and just the narrowing 
of incisive canal was observed in patients with BRONJ 
(21). This sign was deemed late as a result of progressi-
ve sclerotic changes (9,25).
The formation of new periosteal bone could not be 
found in the present study. As it has been detected in ad-
vanced BRONJ stage (9,12,14,15), this might reflect the 
only two patients at BRONJ stage 3. The involvement 
of maxilla in our study manifested mainly as maxillary 
sinus alteration which was a common finding in areas 
with and without osteonecrosis. The thickening of maxi-
llary sinus cortical was more recurrent in BRONJ areas. 
These maxillary manifestations were characteristics of 
middle to advanced BRONJ stages (9,12,14).
Finally, we acknowledge certain limitations to this 
study. First, we must admit that this study reveals the 
disadvantages of retrospective studies only with tomo-
graphic analysis without clinical features, and second, 
we must address the problems of single-center BRONJ 
studies in general. Additionally, we consecutively inclu-
ded 16 female patients and only 5 male patients with 
BRONJ in our study, leading to a marked female ma-
jority in our patient population. Although jaw bones of 
both genders might be considered as equally susceptible 
to side effects from bisphosphonate treatment, subtle 
gender-specific differences could not be ruled out with 
certainty.
In BRONJ, bone alterations vary greatly in exposed and 
unexposed in intraoral areas and most of them can be 
seen throughout all stages of the disease. However, one 
aspect of the present study should call our attention: the 
combination of high frequency of persistent extraction 
sockets in the region of BRONJ lesions and high fre-
quency of widening of periodontal ligament space in 
areas other than involved in BRONJ lesions. This re-
flects the very important role in preventing dental and 
periodontal diseases (dental and periodontal tissues) in 
patients with or at risk of developing BRONJ. Thus, 
preventive measures should be prioritized for patients 
exposed to anti-resorptive drugs.
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